Dr. Lasky joined The Column Group in 2014 and has more than 40 years of experience in the biotechnology industry. In 1981, he was a founding scientist of Genetics Institute, acquired by Wyeth, one of the earliest biotechnology companies. He was subsequently a leading scientist at Genentech and eventually a Genentech Fellow. He worked in various disciplines including vaccinology, immunology, stem cell biology, cellular signaling mechanisms, and monoclonal antibody therapy of tumors. He is a co-author on over 135 publications and a co-inventor on 37 issued and pending patents. In addition to Synthekine, Dr. Lasky currently serves on Accent Therapeutic’s board of directors and serves on the scientific advisory board for Ribon Therapeutics and Eikon Therapeutics. Previously, he served on the boards of eFFECTOR Therapeutics and Revolution Medicines. Dr. Lasky received his B.A. and Ph.D. in Molecular Biology from the University of California, Los Angeles and completed his post-doctoral studies at The California Institute of Technology.